Recent Updates
Recently added Catalysts
CAPR

CAPRICOR THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

Key Takeaway: CONSOLIDATED BALANCE SHEETS September 30, 2014 Pro-Forma Adjustments Pro-Forma September 30, 2014 ASSETS CURRENT ASSETS Cash and cash equivalents $ 9,805,435 $ 17,052,029 (1) $ 26,857,464 Marketable securities 325,318 325,318 Restricted

Full Press Release Details

CONSOLIDATED BALANCE SHEETS
September 30, 2014 Pro-Forma Adjustments Pro-Forma September 30, 2014
ASSETS
CURRENT ASSETS
Cash and cash equivalents $ 9,805,435 $ 17,052,029 (1) $ 26,857,464
Marketable securities 325,318 325,318
Restricted cash 3,699,660 3,699,660
Grant receivable 259,800 259,800
Interest receivable 823 823
Prepaid expenses and other current assets 105,100 105,100
TOTAL CURRENT ASSETS 14,196,136 17,052,029 (1) 31,248,165
PROPERTY AND EQUIPMENT, at cost
Furniture and equipment 38,850 38,850
Laboratory equipment 262,451 262,451
Leasehold improvements 23,744 23,744
325,045 325,045
Less accumulated depreciation (100,499 ) (100,499 )
NET PROPERTY AND EQUIPMENT 224,546 224,546
OTHER ASSETS
Patents, net of accumulated amortization of $35,722 at September 30, 2014 288,474 288,474
Loan fees, net of accumulated amortization of $11,757 at September 30, 2014 18,243 18,243
In-process research and development, net of accumulated amortization of $0 at September 30, 2014 1,500,000 1,500,000
Deposits 55,320 55,320
TOTAL ASSETS $ 16,282,719 $ 17,052,029 (1) $ 33,334,748
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable and accrued expenses $ 1,613,066 $ 1,613,066
Accounts payable and accrued expenses, related party 300,855 300,855
Sub-award payable, related party - -
Accrued royalties 111,651 111,651
Deferred income, current 4,166,667 4,166,667
TOTAL CURRENT LIABILITIES 6,192,239 6,192,239
LONG-TERM LIABILITIES
Deferred income, net of current portion 5,208,332 5,208,332
Loan payable 9,155,857 9,155,857
Accrued interest 198,256 198,256
TOTAL LONG-TERM LIABILITIES 14,562,445 14,562,445
TOTAL LIABILITIES 20,754,684 20,754,684
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding - -
Common stock, $0.001 par value, 50,000,000 shares authorized, 11,703,774 shares issued and outstanding at September 30, 2014, 16,201,641 shares issued and outstanding Pro-Forma September 30, 2014 11,704 4,498 (1) 16,202
Additional paid-in capital 15,905,010 17,047,531 (1) 32,952,541
Subscription receivable - - -
Accumulated other comprehensive loss (1,607 ) (1,607 )
Deficit accumulated during the development stage (20,387,072 ) (20,387,072 )
TOTAL STOCKHOLDERS' EQUITY (DEFICIT) (4,471,965 ) 17,052,029 (1) 12,580,064
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) $ 16,282,719 $ 17,052,029 (1) $ 33,334,748
(1) To reflect the approximate $17,052,029 of cash received
from investors in connection with the private placements.
Last updated: Feb 6, 2015